EUCTR2006-002088-18-GB进行中（未招募）1 期
An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Male or female patients aged 18 to 65 years with a body mass index (BMI) between 18 and 32 kg/m2.
- •2. Has documentary evidence of having been diagnosed for narcolepsy, conforming to the International Classification of Sleep Disorder (ICSD-2) criteria for either narcolepsy with cataplexy or narcolepsy without cataplexy to include:
- •The patient has a complaint of excessive daytime sleepiness occurring almost daily for at least three months.
- •The mean sleep latency of the screening MSLT is less than or equal to eight minutes and two or more SOREMPs are observed following sufficient nocturnal sleep on the previous night (as documented by the PSG prior to the MSLT).
- •3. A female patient is eligible to enter and participate in the study if she is of:
- •a. Non-childbearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal) including any female who:
- •Has had a documented hysterectomy, or,
- •Has had a documented bilateral oophorectomy (ovariectomy), or,
- •Is post-menopausal (a demonstration of total cessation of menses for one year).
- •b. Child bearing potential, has a negative pregnancy test (serum) at screening and agrees to complete abstinence from intercourse from two weeks prior to administration of the study drug and throughout the study until the first menstruation after 5 half-lives have elapsed from the last dose of study medication.
- •c. Child bearing potential (e.g. age), has a negative pregnancy test (serum) at screening and has undergone, or confirms regular use of one of the following:
- •Female sterilisation (i.e. documented bilateral tubal ligation), or,
- •Sterilisation of male partner (i.e. vasectomy); or,
- •Practising a clinically accepted method of contraception (with a failure rate of <1% a year) during the study and for at least one month prior to baseline and one month following completion of the study. Acceptable methods are use of a barrier method (condom, diaphragm) or intrauterine device (IUD) in combination with hormonal methods (oral, implanted or transdermal). Individually hormonal, barrier or IUD methods alone are not acceptable.
- •4. For male patients,
- •a. A willingness to abstain from sexual intercourse (including with pregnant or lactating women) from the time of the first dose of study medication until 84 days after the administration of the last dose of study medication.
- •b. A willingness to use a condom/spermicide in addition to having their female partner use another form of contraception such as an intra-uterine device (IUD), barrier methods (e.g. condom or occlusive cap (diaphragm or cervical vault/caps)), oral contraceptives, injectable progesterone, subdermal implants or a bilateral tubal ligation if the woman could become pregnant from the time of the first dose of study medication until the post-study follow-up visit is complete and for 84 days after the administration of the last dose of study medication.
- •5. Agreement from the patient to refrain from driving or operating heavy machinery for the du
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1. As a result of the medical interview, and other screening procedures the investigator considers the patient unfit to participate in the study (based on medical history, review of 12 Lead ECG, EEG, laboratory parameters, vital signs, physical examination).
- •2. The subject has a positive pre-study Hepatitis B surface antigen and/or positive Hepatitis C antibody result.
- •3. History or presence of major psychiatric disorder, such as schizophrenia, major depressive disorder, bipolar affective disorder or any other condition that could account for their narcolepsy symptoms.
- •4. Presence of depression as defined by Hospital Anxiety and Depression Scale (HADS) depression score >= 8, or presence of anxiety disorder as defined by HADS anxiety score >= 8.
- •5. A definite or suspected family history (in first degree relatives) of clinically significant psychiatric disorders including anxiety, depression, self-harm, bipolar disorder and schizophrenia.
- •6. History of significant head trauma in previous 12 months.
- •7. The patient has any abnormality on diagnostic EEG (with the exception of signs of sleepiness), or history or presence of seizures or risk factors for seizure.
- •8. The patient is unable to abstain from the use of non-selective MAOIs or MAO-A inhibitors (e.g. phenelzine) and potent PGP inhibitors (e.g., itraconazole and ketoconazole) for 2 weeks before the first dose of study medication.
- •9. The patient is unable to withdraw from any medication primarily prescribed as a treatment of daytime hypersomnolence (e.g., methylphenidate, permoline or dexamphetamine, modafinil). Patients are required to stop taking these treatments for at least 48 hours before the first dose of study medication.
- •10. Patients should not be living on their own (i.e. should be living with a carer) during the out-patient parts of the study. The person living with the patient will need to be aware of the patient’s participation in the study and must be willing to contact the investigator for the patient if required.
- •11. The patient has participated in another clinical trial with an investigational drug within the previous 3 months of study start.
- •12. The patient has a significant and recent (within 1 year) history of drug or alcohol abuse.
- •13. Patient who is pregnant or breast feeding.
- •14. The patient has had a history or presence of drug or other significant allergy that, in the opinion of the responsible physician, contra-indicated their participation.
- •15. The patient has any other medical condition that in the opinion of the investigator and GSK medical monitor would compromise the safety of the subject or the subjects’ suitability to complete the study, examples include but are not limited to:
- •The patient meets the essential diagnostic criteria for Restless Leg Syndrome (RLS), as assessed by the RLS questionnaire (International Restless Legs Syndrome Study Group (IRLSSG)).
- •An apnea-hypopnea index (AHI) larger than 10 during any PSG night up to and including the baseline night (Day -2).
- •A periodic limb movement arousal index (PLMAI) larger than 15 during any PSG night
研究者
相似试验
进行中（未招募）
1 期
An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.arcolepsyMedDRA version: 8.1Level: LLTClassification code 10028713Term: NarcolepsyEUCTR2006-002088-18-NLGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.EUCTR2006-002088-18-DEGlaxoSmithKline Research & Development Ltd120
进行中（未招募）
不适用
An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.EUCTR2006-002088-18-ATGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
不适用
An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.arcolepsyMedDRA version: 8.1Level: LLTClassification code 10028713Term: NarcolepsyEUCTR2006-002088-18-FIGlaxoSmithKline Research & Development Ltd140
进行中（未招募）
1 期
An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000327-27-Outside-EU/EEAIonis Pharmaceuticals, Inc.34